Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CarMax Fiscal Q2 Results Show Progress Ahead of November Strategic Update, RBC Says

CarMax Fiscal Q2 Results Show Progress Ahead of November Strategic Update, RBC Says

MT newswireMT newswire2026/09/30 15:24
11:24 AM EDT, 09/30/2026 (MT Newswires) -- CarMax (KMX) fiscal Q2 results showed another solid quarter with comparable used-vehicle sales momentum and the resumption of share buybacks boosting confidence in the company's trajectory, RBC Capital Markets said in a note emailed Wednesday. CarMax reported Q2 operating revenue up 20% to $7.88 billion, ahead of the Street's expectation for $7.09 billion, while quarterly earnings jumped to $1.16 per share from $0.64 a year earlier. RBC said it was "encouraged" by the company's progress and is now looking forward to its strategic update on Nov. 3. The investment firm raised CarMax's fiscal Q3 retail comp unit estimate to 15% growth from 5% growth previously, and the net sales estimate to 15% growth from a 3% increase previously. RBC also now expects Q3 adjusted earnings per share of $0.58 up from $0.34 previously. For fiscal 2027 and fiscal 2028, RBC now expects the company to post adjusted EPS of $3.32 and $3.76, up from $2.62 and $2.98 previously. The investment firm added it will be "looking for data points to increase our conviction in FY'28 delivery to get more constructive on the name." CarMax benefits from established omni-channel capabilities, attractive older vehicle offers and strong cash flow, RBC said. RBC has a sector perform rating on CarMax and lifted the company's price target to $56 from $45. Price: 56.61, Change: -2.62, Percent Change: -4.42
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56

Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go

Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.

智通财经•2026/10/13 01:36